Skip to main content

Table 1 Baseline characteristics of the patients (N = 439)

From: Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment

Female, n (%) 296 (67.4%)
Age (yrs.), mean (SD) 59.8 (10.8)
Disease duration (yrs.), median (IQR) 10 (6–17)
BMI, mean (SD) 25.9 (4.3)
 Normal BMI (18.5–25), n (%) 174 (39.6%)
RF positive, n (%) 270 (67.3%)
ACPA positive, n (%) 277 (69.1%)
Erosive disease, n (%) 252 (62.8%)
ESR, median (IQR) 9.0 (5–17)
TJC28, median (IQR) 0 (0–1)
SJC28, median (IQR) 0 (0–0)
PGA, median (IQR) 20.7 (9.0–28.1)
DAS28-ESR, mean (SD) 2.0 (0.8)
MBDA score, mean (SD) 30.2 (12.6)
 Low (< 30) or moderate (30–44), n (%) 375 (85.4%)
Type of TNFi, n (%)
 Etanercept 176 (40.1%)
 Adalimumab 225 (51.3%)
 Infliximab 22 (5.0%)
 Golimumab 14 (3.2%)
 Certolizumab 2 (0.5%)
Number of TNFi, n (%)
 1st 379 (86.5%)
 2nd 50 (11.4%)
 3rd 9 (2.1%)
csDMARD, n (%)
 Methotrexate 362 (82.5%)
 Methotrexate + glucocorticoids 20 (4.6%)
 Glucocorticoids 6 (1.4%)
 Other csDMARD 29 (6.6%)
 No DMARD 22 (5.0%)
  1. TNFi tumor necrosis factor-alpha inhibitors, DAS28 disease activity score in 28 joints, BMI body mass index, RF rheumatoid factor, ACPA anti-cyclic citrullinated peptide antibodies, ESR erythrocyte sedimentation rate, CRP C-reactive protein, TJC28 28-joint tender joint count, SJC28 28-joint swollen joint count, PGA patient global assessment, MBDA multi-biomarker disease activity, csDMARD conventional synthetic disease modifying anti-rheumatic drug